» Articles » PMID: 19890883

Genome-wide Transcriptome Analyses Reveal P53 Inactivation Mediated Loss of MiR-34a Expression in Malignant Peripheral Nerve Sheath Tumours

Abstract

Malignant peripheral nerve sheath tumours (MPNSTs) are aggressive soft tissue tumours that occur either sporadically or in patients with neurofibromatosis type 1. The malignant transformation of the benign neurofibroma to MPNST is incompletely understood at the molecular level. We have determined the gene expression signature for benign and malignant PNSTs and found that the major trend in malignant transformation from neurofibroma to MPNST consists of the loss of expression of a large number of genes, rather than widespread increase in gene expression. Relatively few genes are expressed at higher levels in MPNSTs and these include genes involved in cell proliferation and genes implicated in tumour metastasis. In addition, a gene expression signature indicating p53 inactivation is seen in the majority of MPNSTs. Subsequent microRNA profiling of benign and malignant PNSTs indicated a relative down-regulation of miR-34a in most MPNSTs compared to neurofibromas. In vitro studies using the cell lines MPNST-14 (NF1 mutant) and MPNST-724 (from a non-NF1 individual) show that exogenous expression of p53 or miR-34a promotes apoptotic cell death. In addition, exogenous expression of p53 in MPNST cells induces miR-34a and other miRNAs. Our data show that p53 inactivation and subsequent loss of expression of miR-34a may significantly contribute to the MPNST development. Collectively, our findings suggest that deregulation of miRNAs has a potential role in the malignant transformation process in peripheral nerve sheath tumours.

Citing Articles

Dysregulation of miRNAs in Soft Tissue Sarcomas.

Zoroddu S, Lucariello A, De Luca A, Bagella L Cells. 2024; 13(22).

PMID: 39594601 PMC: 11592554. DOI: 10.3390/cells13221853.


Multifunctional elastin-like polypeptide nanocarriers for efficient miRNA delivery in cancer therapy.

Hong J, Sim D, Lee B, Sarangthem V, Park R J Nanobiotechnology. 2024; 22(1):293.

PMID: 38802812 PMC: 11131307. DOI: 10.1186/s12951-024-02559-5.


Small Non-Coding RNAs in Soft-Tissue Sarcomas: State of the Art and Future Directions.

La Ferlita A, Sp N, Goryunova M, Nigita G, Pollock R, Croce C Mol Cancer Res. 2023; 21(6):511-524.

PMID: 37052491 PMC: 10238653. DOI: 10.1158/1541-7786.MCR-22-1008.


MicroRNAs in the Pathogenesis, Prognostication and Prediction of Treatment Resistance in Soft Tissue Sarcomas.

Teo A, Lim V, Yang V Cancers (Basel). 2023; 15(3).

PMID: 36765536 PMC: 9913386. DOI: 10.3390/cancers15030577.


Neurofibroma Development in Neurofibromatosis Type 1: Insights from Cellular Origin and Schwann Cell Lineage Development.

Ge L, Xing M, Zhang H, Wang Z Cancers (Basel). 2022; 14(18).

PMID: 36139671 PMC: 9497298. DOI: 10.3390/cancers14184513.


References
1.
Ling B, Wu J, Miller S, Monk K, Shamekh R, Rizvi T . Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell. 2005; 7(1):65-75. PMC: 2854500. DOI: 10.1016/j.ccr.2004.10.016. View

2.
Park S, Lee J, Ha M, Nam J, Kim V . miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol. 2008; 16(1):23-9. DOI: 10.1038/nsmb.1533. View

3.
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A . UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 2003; 63(14):4167-73. View

4.
Perrone F, Da Riva L, Orsenigo M, Losa M, Jocolle G, Millefanti C . PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol. 2009; 11(6):725-36. PMC: 2802393. DOI: 10.1215/15228517-2009-003. View

5.
Chang T, Wentzel E, Kent O, Ramachandran K, Mullendore M, Lee K . Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007; 26(5):745-52. PMC: 1939978. DOI: 10.1016/j.molcel.2007.05.010. View